Amazon Secures 200 MW Wind Power Deals in Sweden 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
(4) - EconoTimes)
Add as a preferred source on Google
CAMBRIDGE, Mass., March 30, 2018 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on March 30, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to twelve individuals hired by Sarepta in March 2018. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 42,443 shares of Sarepta's common stock. The options have an exercise price of $74.09 per share. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]
